{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-147093","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2024-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.428139+00:00","generated_at":"2026-06-01T08:44:51.882321+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"4D Molecular Therapeutics stockholders elect David Kirn as Class I director and ratify PwC as auditor","bullets":["David Kirn, M.D. elected as Class I director with 35,630,613 votes for, 7,849,441 withheld, and 1,574,659 broker non-votes.","Ratification of PricewaterhouseCoopers LLP as independent auditor for FY2024: 45,032,000 for, 21,052 against, 1,661 abstain.","Annual Meeting held on May 21, 2024; 45,054,713 of 51,157,472 outstanding shares voted."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-147093","json":"https://secwatch.observer/filing/0001193125-24-147093.json","markdown":"https://secwatch.observer/filing/0001193125-24-147093.md","text":"https://secwatch.observer/filing/0001193125-24-147093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312524147093/0001193125-24-147093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312524147093/d649174d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:44:51.882321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}